Empowered Funds LLC Has $623,000 Holdings in DexCom, Inc. (NASDAQ:DXCM)

Empowered Funds LLC grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 37.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,010 shares of the medical device company’s stock after purchasing an additional 2,163 shares during the period. Empowered Funds LLC’s holdings in DexCom were worth $623,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of DexCom by 15.4% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 47,263 shares of the medical device company’s stock valued at $3,676,000 after purchasing an additional 6,290 shares during the last quarter. Consolidated Portfolio Review Corp acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $220,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of DexCom by 13.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 147,911 shares of the medical device company’s stock valued at $11,768,000 after purchasing an additional 17,650 shares during the last quarter. Stratos Wealth Partners LTD. acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $201,000. Finally, E. Ohman J or Asset Management AB raised its holdings in shares of DexCom by 12.1% in the fourth quarter. E. Ohman J or Asset Management AB now owns 17,600 shares of the medical device company’s stock valued at $1,369,000 after purchasing an additional 1,900 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DXCM. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Sanford C. Bernstein raised their target price on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Royal Bank of Canada decreased their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and raised their target price for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Finally, JPMorgan Chase & Co. raised their target price on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.06.

Insider Activity

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,083 shares of company stock valued at $3,309,794. 0.30% of the stock is owned by company insiders.

DexCom Trading Up 1.6 %

Shares of DexCom stock opened at $90.53 on Wednesday. The firm has a 50-day moving average of $82.65 and a 200-day moving average of $75.62. The stock has a market cap of $35.36 billion, a PE ratio of 54.21, a PEG ratio of 2.26 and a beta of 1.14. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 17.22% and a return on equity of 31.40%. As a group, sell-side analysts forecast that DexCom, Inc. will post 1.69 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.